Phase III study of garenoxacin in patients with secondary infection of chronic respiratory diseases

Hiroyuki Kobayashi, Yusuke Tanigawara, Akira Watanabe, Nobuki Aoki, Yasuyuki Sano, Shigeki Odagiri, Yoshihito Niki, Shigeru Kohno, Atsushi Saito

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The efficacy and safety of garenoxacin mesilate hydrate(GRNX), new oral des-fluoroquinolone antimicrobial, were investigated in patients with secondary infection occurred on chronic respiratory disorders. Patients were treated with GRNX 400 mg once daily for 10 days. Plasma concentration of GRNX in each patient was determined and the obtained clinical results were analysed based on pharmacokinetics(PK) and pharmacokinetics/pharmacodynamics(PK/PD) parameters. Clinical efficacy rates were 87.8% (108/123) at the end of treatment and 83.7% (103/123) at the 7th day of post-treatment. Bacteriological eradication rates were 89.6% (60/67) and 85.1% (57/67) at the above time points. Eradication rates of causative organisms were 100% (13/13) in Streptococcus pneumoniae, 7/8 in Staphylococcus aureus, 100% (28/28) in Haemophilus influenzae and 8/8 in Moraxella (Branhamella) catarrhalis at the end of treatment. All penicillin-resistant S. pneumoniae(PRSP) including penicillin-intermediate resistant S. pneumoniae(PISP) were eradicated. Drug-related adverse events were observed in 19 patients (26 events), the incidence rate was 14.0% (19/136). Gastrointestinal disorders including 4 cases of diarrhea (2.9%), 3 of loose stool (2.2%) and 3 of vomiting (2.2%) were frequently observed. Laboratory abnormalities were observed in 26 patients (19.3%). Frequent abnormalities were 14 cases of AST elevation (10.4%), 13 of ALT elevation (9.6%) and 5 of serum amylase elevation (3.8%). No relationship was observed between PK parameters (AUC0-24 and Cmax) and incidence of adverse events. 90.9% of patient in this study exceeded the target value of fAUC0-24/MIC > 50. Clinical efficacy at the 7th day of post-treatment was 91.7% (55/60) in those cases whose target value was more than 50, but it was only 3/6 in those whose target value was less than 50. Similar results were obtained in studies in US and EU. From aboves, it indicates that GRNX is a beneficial antimicrobial agent for secondary infection of chronic respiratory diseases.

Original languageEnglish
Pages (from-to)144-161
Number of pages18
JournalJapanese Journal of Chemotherapy
Volume55
Issue numberSUPPL. 1
Publication statusPublished - 2007 Oct

Fingerprint

Coinfection
Chronic Disease
Streptococcus pneumoniae
Pharmacokinetics
Penicillins
Moraxella (Branhamella) catarrhalis
Mesylates
Fluoroquinolones
Incidence
Haemophilus influenzae
Therapeutics
Amylases
Anti-Infective Agents
Drug-Related Side Effects and Adverse Reactions
Vomiting
Staphylococcus aureus
garenoxacin
Diarrhea
Safety
Serum

ASJC Scopus subject areas

  • Pharmacology

Cite this

Kobayashi, H., Tanigawara, Y., Watanabe, A., Aoki, N., Sano, Y., Odagiri, S., ... Saito, A. (2007). Phase III study of garenoxacin in patients with secondary infection of chronic respiratory diseases. Japanese Journal of Chemotherapy, 55(SUPPL. 1), 144-161.

Phase III study of garenoxacin in patients with secondary infection of chronic respiratory diseases. / Kobayashi, Hiroyuki; Tanigawara, Yusuke; Watanabe, Akira; Aoki, Nobuki; Sano, Yasuyuki; Odagiri, Shigeki; Niki, Yoshihito; Kohno, Shigeru; Saito, Atsushi.

In: Japanese Journal of Chemotherapy, Vol. 55, No. SUPPL. 1, 10.2007, p. 144-161.

Research output: Contribution to journalArticle

Kobayashi, H, Tanigawara, Y, Watanabe, A, Aoki, N, Sano, Y, Odagiri, S, Niki, Y, Kohno, S & Saito, A 2007, 'Phase III study of garenoxacin in patients with secondary infection of chronic respiratory diseases', Japanese Journal of Chemotherapy, vol. 55, no. SUPPL. 1, pp. 144-161.
Kobayashi, Hiroyuki ; Tanigawara, Yusuke ; Watanabe, Akira ; Aoki, Nobuki ; Sano, Yasuyuki ; Odagiri, Shigeki ; Niki, Yoshihito ; Kohno, Shigeru ; Saito, Atsushi. / Phase III study of garenoxacin in patients with secondary infection of chronic respiratory diseases. In: Japanese Journal of Chemotherapy. 2007 ; Vol. 55, No. SUPPL. 1. pp. 144-161.
@article{bcff29abdc1b4f6e8bb54dc7be597104,
title = "Phase III study of garenoxacin in patients with secondary infection of chronic respiratory diseases",
abstract = "The efficacy and safety of garenoxacin mesilate hydrate(GRNX), new oral des-fluoroquinolone antimicrobial, were investigated in patients with secondary infection occurred on chronic respiratory disorders. Patients were treated with GRNX 400 mg once daily for 10 days. Plasma concentration of GRNX in each patient was determined and the obtained clinical results were analysed based on pharmacokinetics(PK) and pharmacokinetics/pharmacodynamics(PK/PD) parameters. Clinical efficacy rates were 87.8{\%} (108/123) at the end of treatment and 83.7{\%} (103/123) at the 7th day of post-treatment. Bacteriological eradication rates were 89.6{\%} (60/67) and 85.1{\%} (57/67) at the above time points. Eradication rates of causative organisms were 100{\%} (13/13) in Streptococcus pneumoniae, 7/8 in Staphylococcus aureus, 100{\%} (28/28) in Haemophilus influenzae and 8/8 in Moraxella (Branhamella) catarrhalis at the end of treatment. All penicillin-resistant S. pneumoniae(PRSP) including penicillin-intermediate resistant S. pneumoniae(PISP) were eradicated. Drug-related adverse events were observed in 19 patients (26 events), the incidence rate was 14.0{\%} (19/136). Gastrointestinal disorders including 4 cases of diarrhea (2.9{\%}), 3 of loose stool (2.2{\%}) and 3 of vomiting (2.2{\%}) were frequently observed. Laboratory abnormalities were observed in 26 patients (19.3{\%}). Frequent abnormalities were 14 cases of AST elevation (10.4{\%}), 13 of ALT elevation (9.6{\%}) and 5 of serum amylase elevation (3.8{\%}). No relationship was observed between PK parameters (AUC0-24 and Cmax) and incidence of adverse events. 90.9{\%} of patient in this study exceeded the target value of fAUC0-24/MIC > 50. Clinical efficacy at the 7th day of post-treatment was 91.7{\%} (55/60) in those cases whose target value was more than 50, but it was only 3/6 in those whose target value was less than 50. Similar results were obtained in studies in US and EU. From aboves, it indicates that GRNX is a beneficial antimicrobial agent for secondary infection of chronic respiratory diseases.",
author = "Hiroyuki Kobayashi and Yusuke Tanigawara and Akira Watanabe and Nobuki Aoki and Yasuyuki Sano and Shigeki Odagiri and Yoshihito Niki and Shigeru Kohno and Atsushi Saito",
year = "2007",
month = "10",
language = "English",
volume = "55",
pages = "144--161",
journal = "Japanese Journal of Chemotherapy",
issn = "1340-7007",
publisher = "Japan Society of Chemotherapy",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Phase III study of garenoxacin in patients with secondary infection of chronic respiratory diseases

AU - Kobayashi, Hiroyuki

AU - Tanigawara, Yusuke

AU - Watanabe, Akira

AU - Aoki, Nobuki

AU - Sano, Yasuyuki

AU - Odagiri, Shigeki

AU - Niki, Yoshihito

AU - Kohno, Shigeru

AU - Saito, Atsushi

PY - 2007/10

Y1 - 2007/10

N2 - The efficacy and safety of garenoxacin mesilate hydrate(GRNX), new oral des-fluoroquinolone antimicrobial, were investigated in patients with secondary infection occurred on chronic respiratory disorders. Patients were treated with GRNX 400 mg once daily for 10 days. Plasma concentration of GRNX in each patient was determined and the obtained clinical results were analysed based on pharmacokinetics(PK) and pharmacokinetics/pharmacodynamics(PK/PD) parameters. Clinical efficacy rates were 87.8% (108/123) at the end of treatment and 83.7% (103/123) at the 7th day of post-treatment. Bacteriological eradication rates were 89.6% (60/67) and 85.1% (57/67) at the above time points. Eradication rates of causative organisms were 100% (13/13) in Streptococcus pneumoniae, 7/8 in Staphylococcus aureus, 100% (28/28) in Haemophilus influenzae and 8/8 in Moraxella (Branhamella) catarrhalis at the end of treatment. All penicillin-resistant S. pneumoniae(PRSP) including penicillin-intermediate resistant S. pneumoniae(PISP) were eradicated. Drug-related adverse events were observed in 19 patients (26 events), the incidence rate was 14.0% (19/136). Gastrointestinal disorders including 4 cases of diarrhea (2.9%), 3 of loose stool (2.2%) and 3 of vomiting (2.2%) were frequently observed. Laboratory abnormalities were observed in 26 patients (19.3%). Frequent abnormalities were 14 cases of AST elevation (10.4%), 13 of ALT elevation (9.6%) and 5 of serum amylase elevation (3.8%). No relationship was observed between PK parameters (AUC0-24 and Cmax) and incidence of adverse events. 90.9% of patient in this study exceeded the target value of fAUC0-24/MIC > 50. Clinical efficacy at the 7th day of post-treatment was 91.7% (55/60) in those cases whose target value was more than 50, but it was only 3/6 in those whose target value was less than 50. Similar results were obtained in studies in US and EU. From aboves, it indicates that GRNX is a beneficial antimicrobial agent for secondary infection of chronic respiratory diseases.

AB - The efficacy and safety of garenoxacin mesilate hydrate(GRNX), new oral des-fluoroquinolone antimicrobial, were investigated in patients with secondary infection occurred on chronic respiratory disorders. Patients were treated with GRNX 400 mg once daily for 10 days. Plasma concentration of GRNX in each patient was determined and the obtained clinical results were analysed based on pharmacokinetics(PK) and pharmacokinetics/pharmacodynamics(PK/PD) parameters. Clinical efficacy rates were 87.8% (108/123) at the end of treatment and 83.7% (103/123) at the 7th day of post-treatment. Bacteriological eradication rates were 89.6% (60/67) and 85.1% (57/67) at the above time points. Eradication rates of causative organisms were 100% (13/13) in Streptococcus pneumoniae, 7/8 in Staphylococcus aureus, 100% (28/28) in Haemophilus influenzae and 8/8 in Moraxella (Branhamella) catarrhalis at the end of treatment. All penicillin-resistant S. pneumoniae(PRSP) including penicillin-intermediate resistant S. pneumoniae(PISP) were eradicated. Drug-related adverse events were observed in 19 patients (26 events), the incidence rate was 14.0% (19/136). Gastrointestinal disorders including 4 cases of diarrhea (2.9%), 3 of loose stool (2.2%) and 3 of vomiting (2.2%) were frequently observed. Laboratory abnormalities were observed in 26 patients (19.3%). Frequent abnormalities were 14 cases of AST elevation (10.4%), 13 of ALT elevation (9.6%) and 5 of serum amylase elevation (3.8%). No relationship was observed between PK parameters (AUC0-24 and Cmax) and incidence of adverse events. 90.9% of patient in this study exceeded the target value of fAUC0-24/MIC > 50. Clinical efficacy at the 7th day of post-treatment was 91.7% (55/60) in those cases whose target value was more than 50, but it was only 3/6 in those whose target value was less than 50. Similar results were obtained in studies in US and EU. From aboves, it indicates that GRNX is a beneficial antimicrobial agent for secondary infection of chronic respiratory diseases.

UR - http://www.scopus.com/inward/record.url?scp=35348956016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348956016&partnerID=8YFLogxK

M3 - Article

VL - 55

SP - 144

EP - 161

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

SN - 1340-7007

IS - SUPPL. 1

ER -